{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"27.6","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"title":"CC or CT genotype"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.4","upperLimit":"68.7","value":"44.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"High-risk CEP72 genotype (TT at rs924607)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"description":"Percentage of patients who developed at least 1 episode of grade 2 to 4 neuropathy.","dispersionType":"95% Confidence Interval","groups":[{"description":"This analysis looks at all eligible patients with CC or CT genotypes as well as all eligible patients with the high-risk CEP72 genotype (TT at rs924607).","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"The total number of patients for CC or CT genotype is 81 and for high-risk CEP72 genotype is 18. No related by arm data were provided.","reportingStatus":"POSTED","timeFrame":"Up to 107 weeks","title":"Frequency and Severity of Adverse Effects","type":"SECONDARY","unitOfMeasure":"percentage of participants"}